Midatech Pharma PLC (MTP)
Stock Price:
$2.00 USD
0.07 (3.63%)
Updated Aug 12, 2020 1:05 PM EDT - Market open
Key Info
| Market Cap |
24.22M |
| Revenue (ttm) |
878,697 |
| Net Income (ttm) |
-13.15M |
| Shares Out |
12.11M |
| EPS (ttm) |
-0.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$2.00 |
| Previous Close |
$1.93 |
| Change ($) |
0.07 |
| Change (%) |
3.63% |
| Day's Open |
1.96 |
| Day's Range |
1.93 - 2.00 |
| Day's Volume |
80,359 |
| 52-Week Range |
0.86 - 8.50 |
More Stats
| Market Cap |
24.22M |
| Enterprise Value |
17.90M |
| Earnings Date (est) |
Sep 24, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
12.11M |
| Float |
6.33M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.85 |
| FCF / Share |
-4.65 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7,975 |
| Short Ratio |
0.15 |
| Short % of Float |
n/a |
| Beta |
1.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
27.56 |
| PB Ratio |
1.00 |
| Revenue |
878,697 |
| Operating Income |
-14.77M |
| Net Income |
-13.15M |
| Free Cash Flow |
-11.37M |
| Net Cash |
6.32M |
| Net Cash / Share |
0.52 |
| Gross Margin |
100.00% |
| Operating Margin |
-1,681.45% |
| Profit Margin |
-1,496.30% |
| FCF Margin |
-1,293.62% |
| ROA |
-27.56% |
| ROE |
-50.10% |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
1,575
Current: $2.00
High
1,575
Target: 1,575
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions GBP.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 0.67 | 1.94 | 0.99 | 1.32 | 1.38 | 0.16 | 0.15 |
| Revenue Growth | -65.22% | 95.96% | -25.25% | -3.78% | 775.8% | 6.8% | - |
| Gross Profit | 0.67 | 1.94 | 0.99 | 1.32 | 1.31 | 0.16 | 0.15 |
| Operating Income | -11.33 | -11.82 | -13.28 | -9.65 | -12.92 | -9.69 | -4.50 |
| Net Income | -10.09 | -15.03 | -16.06 | -20.16 | -10.10 | -8.82 | -4.08 |
| Shares Outstanding | 12.24 | 12.22 | 9.74 | 6.69 | 6.69 | - | - |
| Earnings Per Share | -2.75 | -24.60 | -31.30 | -14.00 | -9.00 | -24.50 | -17.75 |
| Operating Cash Flow | -8.41 | -14.81 | -14.41 | -14.74 | -13.07 | -6.25 | -5.02 |
| Capital Expenditures | -0.31 | -0.22 | -0.71 | -1.35 | -0.92 | -1.03 | -0.05 |
| Free Cash Flow | -8.72 | -15.03 | -15.12 | -16.08 | -13.99 | -7.28 | -5.07 |
| Cash & Equivalents | 10.93 | 2.34 | 13.20 | 17.61 | 16.18 | 30.33 | 2.39 |
| Total Debt | 6.08 | 1.25 | 6.55 | 2.16 | 1.95 | 1.98 | 3.37 |
| Net Cash / Debt | 4.85 | 1.09 | 6.66 | 15.45 | 14.23 | 28.35 | -0.98 |
| Assets | 30.90 | 20.44 | 49.22 | 56.69 | 64.04 | 46.66 | 5.17 |
| Liabilities | 11.34 | 3.52 | 14.55 | 10.97 | 17.15 | 4.67 | 4.41 |
| Book Value | 19.56 | 16.92 | 34.68 | 45.72 | 46.89 | 41.99 | 0.76 |
Numbers in millions GBP, except per-share numbers.
Company Details
| Full Name |
Midatech Pharma PLC |
| Country |
United Kingdom |
| Employees |
65 |
| CEO |
Stephen Anthony Stamp |
Stock Information
| Ticker Symbol |
MTP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MTP |
Description
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.